INTRODUCTION

Normal endothelial functions include control of platelet adhesion, mediation of coagulation and immune function, and control of volume and electrolyte content of body components.1 Endothelial dysfunction is a pathophysiological condition of abnormal process carried out by the endothelium. It is thought to be a key initial step in the development of atherosclerosis and can be used as a prognostic marker in predicting cardiovascular events including stroke and heart attacks.2,3

Endothelial dysfunction can be characterized as the inability of arteries to dilate fully in response to appropriate stimuli.

ENDOTHelial DYSFUNCTION IN THE SMokers CAN Be IMPROVED WITH ORAL CilostAZOL TREATMENT

KYU SEOP KIM, MD, HYUNG SEO PARK, MD, IL SOON JUNG, MD, JAE-HYEONG PARK, MD, PHD, KYE TAEK AHN, MD, SEON-AH JIN, MD, YONG KYU PARK, MD, JUN HYUNG KIM, MD, JAE-HWAN LEE, MD, PHD, SI WAN CHOI, MD, PHD, JIN-OK JEONG, MD, PHD AND IN-WHAN SEONG, MD, PHD

DIVISION OF CARDIOLOGY, DEPARTMENT OF INTERNAL MEDICINE, SCHOOL OF MEDICINE, CHUNGNAM NATIONAL UNIVERSITY, CHUNGNAM NATIONAL UNIVERSITY HOSPITAL, DAEGEON CARDIOCEBROVASCULAR CENTER, DAEGEON, KOREA

BACKGROUND: Smoking is one of well known environmental factors causing endothelial dysfunction and plays important role in the atherosclerosis. We investigated the effect of cilostazol could improve the endothelial dysfunction in smokers with the measurement of flow-mediated dilatation (FMD).

METHODS: We enrolled 10 normal healthy male persons and 20 male smokers without any known cardiovascular diseases. After measurement of baseline FMD, the participants were medicated with oral cilostazol 100 mg bid for two weeks. We checked the follow up FMD after two weeks and compared these values between two groups.

RESULTS: There was no statistical difference of baseline characteristics including age, body mass index, serum cholesterol profiles, serum glucose and high sensitive C-reactive protein between two groups. However, the control group showed significantly higher baseline endothelium-dependent dilatation (EDD) after reactive hyperemia (12.0 ± 4.5 % in the control group vs. 8.0 ± 2.1 % in the smoker group, \( p = 0.001 \)). However, endothelium-independent dilatation (EID) after sublingual administration of nitroglycerin was similar between the two groups (13.6 ± 4.5% in the control group vs. 11.9 ± 4.9% in the smoker group, \( p = 0.681 \)). Two of the smoker group were dropped out due to severe headache. After two weeks of cilostazol therapy, follow-up EDD were significantly increased in two groups (12.0 ± 4.5% to 16.1 ± 3.7%, \( p = 0.034 \) in the control group and 8.0 ± 2.1% to 12.2 ± 5.1%, \( p = 0.003 \) in the smoker group, respectively). However, follow up EID value was not significantly increased compared with baseline value in both groups (13.6 ± 4.5% to 16.1 ± 3.7%, \( p = 0.182 \) in the control group and 11.9 ± 4.9% to 13.7 ± 4.3%, \( p = 0.430 \) in the smoker group, respectively).

CONCLUSION: Oral cilostazol treatment significantly increased the vasodilatory response to reactive hyperemia in two groups. It can be used to improve endothelial function in the patients with endothelial dysfunction caused by cigarette smoking.

KEY WORDS: Endothelial dysfunction · Smoking · Cilostazol.
This can be detected by flow-mediated dilatation (FMD) using temporary arterial occlusion by inflating a blood pressure cuff to high pressures. Flow-mediated changes in conduit artery diameter are caused by shear-stress induced generation of endothelia derived vasoactive mediators including nitric oxides.\(^6\)

Cilostazol (Otsuka Pharmaceutical Co. Tokushima, Japan), 6-[4-[1-cyclohexyl-1H-tetrazol-5-yl]butoxy]-3,4-dihydro-2(1H)-quinolinone, is a 2-oxo-quinoline derivative with anti-thrombotic, vasodilator, antimitogenic and cardiotoxic properties.\(^7\) The compound is a potent inhibitor of phosphodiesterase (PDE)-3. It may be useful for treating chronic arterial occlusive diseases and symptoms of intermittent claudication.\(^8\) Cilostazol inhibits platelet aggregation and has considerable anti-thrombotic effects \textit{in vivo}. Also, this compound relaxes vascular smooth muscle and inhibits mitogenesis and migration of vascular smooth muscle cells. In the heart, it has positive inotropic and chronotropic effects.\(^9\)

This present study investigated the effects of cilostazol that could improve the endothelial dysfunction, especially in young male smokers.

**METHODS**

**SUBJECTS**

We enrolled 10 healthy male non-smokers and 20 active male smokers, average 6.0 ± 3.5 pack years, with matching age and weight. They were all volunteers without having a past or present history of coronary diseases and the results of clinical laboratory tests showing no signs of hypertension, dyslipidemia or diabetes. They filled up the informed consent. Total 200 mg/day of oral cilostazol was administered divided into morning and evening for two weeks. The levels of smoking in the smoker group were remained constantly during the study period.

**VASCULAR ENDOTHELIAL FUNCTION TEST**

FMD was measured according to the methods of previously reported article by Celermajer et al.\(^5\) Each participants rested for about 20 minutes, and their internal diameter of the brachial artery were measured with a Sequoia 512 (Siemens Medical Solutions, Mountain View, CA) equipped with a 10-MHz linear ultrasound probe.

The diameter of the brachial artery was measured in the response to an increase in blood flow (causing shear-stress) during reactive hyperemia (induced by transient inflation of a blood pressure cuff). This leads to endothelium-dependent dilatation (EDD). Endothelium-independent dilatation (EID) was defined as a proportional increase in the diameter to sublingual nitroglycerin, an endothelium-independent dilator. The brachial artery was scanned and the diameter measured during four conditions; at baseline, during reactive hyperemia (induced by transient inflation of a sphygmomanometer cuff), 20 minutes after hyperemia and finally after administration of a sublingual nitroglycerin. After measurement of baseline brachial artery diameter (BD0), a sphygmomanometer cuff was used to apply up to 200 mmHg of pressure for 5 minutes around the upper part of the arm. Follow-up brachial artery diameter (BDh) was measured within 5 minutes after deflation of a blood pressure cuff. Another baseline brachial artery diameter (BD1) was measured after 20 minutes of rest after reactive hyperemia. Vasodilator response was obtained (BDn) within 4 minutes after administration of a single high dose (400 mg) of sublingual nitroglycerin tablet.

EDD was calculated according to the following formula:

\[
\frac{(BDh-BD0)}{BD0} \times 100 \%
\]

EID was calculated according to the following formula:

\[
\frac{(BDn-BD1)}{BD1} \times 100 \%
\]

**STATISTICAL ANALYSIS**

We used a commercial program, SPSS version 17.0 (SPSS Inc., Chicago, Illinois, USA) for Microsoft Windows, for statistical analysis. Numeric variables are expressed as mean ± SD. The difference of continuous variables between two groups was analyzed using a nonparametric test (Mann-Whitney U test). The difference between the baseline and follow-up data was analyzed using the paired sample t-test.

Intraobserver and interobserver agreements in FMD were tested using the baseline values of 10 participants according to the statistical methods proposed by Bland and Altman.\(^7\) All measurements were transformed to an equivalent percentage scale of agreement, according to the following formula;

\[
\text{Agreement index} = \frac{100 - |X1st - X2nd|}{(X1st + X2nd)/2}
\]

in which X1st and X2nd are measures obtained in twice-repeated evaluation using same technique in the same patient. The measure of reproducibility was 2 SD of the intraobserver and interobserver agreement indexes. Therefore, these coefficient of variations (COV) were equal to 2 SD of \[
\frac{|X1st - X2nd|}{(X1st + X2nd)/2}
\]

The intraobserver agreement was 90.8% and the COV was 8.9%. The interobserver agreement was 82.8% and the COV was 14.3%. A p value less than 0.05 was considered statistically significant.

**RESULTS**

There was no significant difference in the clinical characteristics including age, body mass index, blood pressure, serum cholesterol profile, high sensitive C-reactive protein, and serum glucose level between two groups (Table 1). There was no significant side-effect associated with use of oral cilostazol except headache. Though majority subjects with headache were well controlled with oral analgesics, two of 20 smokers dropped out because of uncontrolled severe headache.
Baseline EDD was significantly higher in the control group than in the smoker group (12.0 ± 4.5 in the control group vs. 8.0 ± 2.1% in the smoker group, \( p = 0.002 \), Fig. 1A). Baseline EID was similar in two groups (13.6 ± 4.5% in the control group vs. 11.9 ± 4.9% in the smoker group, \( p = 0.681 \), Fig. 1B). After two weeks of oral cilostazol treatment, follow-up EDD values were significantly increased in both groups (control group: 12.0 ± 4.5 to 16.1 ± 3.7%, \( p = 0.041 \), Fig. 2A; smoker group: 8.0 ± 2.1 to 12.2 ± 5.1%, \( p = 0.003 \), Fig. 2B). Follow-up EDD in the control group showed higher value than that of control group (16.1 ± 3.7 in the control group vs. 12.2 ± 5.1% in the smoker group, \( p = 0.018 \)). However, follow up EID value was not significantly increased compared with baseline value in both groups. (13.6 ± 4.5% to 16.1 ± 3.7%, \( p = 0.182 \) in the control group, Fig. 3A; 11.9 ± 4.9% to 13.7 ± 4.3%, \( p = 0.430 \) in the smoker group, Fig. 3B).

**Discussion**

In this FMD study with oral cilostazol, we demonstrated decreased baseline EDD level in the smoker group and significant improvement of EDD with administration of oral cilostazol in this group. However, cilostazol did not change the EID in this group.

Nitric oxide (NO), also known as the endothelium-derived

| Characteristics                | Non-smokers (n = 10) | Smokers (n = 20) | \( p \)-value |
|-------------------------------|----------------------|-----------------|---------------|
| Age (year)                    | 28.0 ± 1.1           | 29.1 ± 1.9      | 0.138         |
| Body mass index (kg/m²)       | 22.5 ± 2.4           | 24.0 ± 2.7      | 0.183         |
| Systolic BP (mmHg)            | 119.6 ± 9.3          | 124.6 ± 12.1    | 0.340         |
| Diastolic BP (mmHg)           | 70.8 ± 8.8           | 71.4 ± 5.7      | 0.909         |
| Total cholesterol (mg/dL)     | 148 ± 21.7           | 163.2 ± 29.0    | 0.190         |
| HDL-cholesterol (mg/dL)       | 46.4 ± 6.3           | 47.0 ± 5.7      | 0.853         |
| Fasting plasma glucose (mg/dL)| 85.1 ± 15.2          | 89.9 ± 11.8     | 0.143         |
| hs-CRP (mg/L)                 | 2.14 ± 1.02          | 1.51 ± 0.38     | 0.165         |

BP: blood pressure, HDL-cholesterol: high density lipoprotein-cholesterol, hs-CRP: high sensitive C-reactive protein

![Fig. 1. Comparison of endothelium-dependent dilatation (EDD) (A) and endothelium-independent dilatation (EID) (B) in the control and smoker group. Data are expressed as the mean ± standard deviation.](image)

![Fig. 2. Effect of cilostazol treatment on endothelium-dependent dilatation (EDD) in the control group (A) and smoker group (B). A significant effect of cilostazol treatment on EDD is observed.](image)
relaxing factor (EDRF), is a chemical compound which is an important signaling molecule in the mammalian bodies. It is biosynthesized endogenously from L-arginine and oxygen by various nitric oxide synthase (NOS). It contributes to vessel homeostasis by inhibiting platelet aggregation, vascular smooth muscle contraction and growth, and leukocyte adhesion to the endothelium. FMD is one of methods to exam endothelial function. Increased shear stress in the arterial wall, usually caused by occlusion of the artery, can open specialized ion channels in the endothelium and infused calcium ions through these channels stimulate endothelial nitric oxide synthase (eNOS). Increased eNOS activity enhanced NO synthesis and elevated NO evokes vasodilation. The vasodilatory effect of NO, EDRF, on the vessel (vasodilation) can be assessed by FMD. Arterial distensibility after reactive hyperemia is influenced by variable factors. FMD can be influenced by a single high-fat meal, mental stress, cigarette smoking, hyperglycemia, and changes in electrolytes (sodium and calcium). Also, EDD can be decreased by theophylline (adrenoreceptor agonist) or ibuprofen (prostaglandin synthesis inhibitor).

Cigarette smoking is one of the well-known risk factors causing endothelial dysfunction and there are strong relationships between cigarette smoking, atherosclerotic burden, and ischemic heart disease. Cigarette smoking induces initial atherosclerosis and promotes cardiovascular disease through multiple mechanisms including vasomotor, neurohormonal, and hematologic dysfunction, and increased oxidative stress. Endothelial dysfunction can be resulted from inhaled cigarette smoke. Smoking as few as 2 cigarettes a day doubles the number of damaged endothelial cells in the blood stream.

There are several drugs improve endothelial dysfunction including angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and nifedipine in the hypertensive patients, statins, fibrates and omega-3 fatty acid in the dyslipidemic patients, metformin and rosiglitazone in the diabetic patients. Few studies have been reported in the improvement of endothelial dysfunction in the smokers. Smoking cessation is one of the well-known methods to restore endothelial dysfunction.

Guthikonda et al. published their study that allopurinol reverses endothelial dysfunction in the heavy smokers. Oida et al. presented that oral cilostazol treatment can be associated with improvement of endothelial dysfunction.

Cilostazol, a selective PDE-3 inhibitor, increases cyclic adenosine mono-phosphate (cAMP) in the platelets and inhibits platelet aggregation. Moreover, increased cAMP in the vascular smooth muscle cells activates protein kinase A and decreases intracellular calcium concentration. These effects result in vasodilation. Yasuda et al. reported that two weeks treatment of oral cilostazol increased tissue blood flow through the pedal vessels through vasodilation in the patients with peripheral arterial occlusive disease. Cilostazol has been approved by the Food and Drug Administration (FDA) in the treatment of peripheral arterial occlusive disease since 1999. Recently, triple combination antiplatelet therapy, aspirin, clopidogrel and cilostazol, has been reported to reduce thrombotic complication and recurrence of restenosis after implantation of coronary stent, especially in the diabetic patients.

Additional effects of cilostazol on the vascular endothelium have been described. Cilostazol has been associated with increased NO production. Ikeda et al. published their study showing cilostazol increased NO production in cultured vascular smooth muscle cells via cAMP pathway. Nakamura et al. reported that cilostazol dilated thoracic aorta via released NO from aortic endothelium. Increased NO production with cilostazol treatment can be associated with increased EDD in our study. Our result is similar to that of the previously reported article by Oida et al. However, the mean age of the participants was younger (late twenties vs. late thirties) and treated dosage was higher (200 mg per day vs. 150 mg per day) in our study. Because of younger age and shorter duration of smoking, the EDD level in our study may be associated with higher value than that of study by Oida et al.

Cilostazol improved reactive hyperemia in these eighteen smokers. This effect can be resulted from the NO production and relaxation of smooth muscle cells in the vessel. Endothelial dysfunction can be resulted from smoking as a result of in-
creased oxidative stresses such as oxygen free radical which disturbs normal endothelial functions. Therefore, cilostazol can improve endothelial dysfunctions caused by cigarette smoking.

In this study, most of participants complained headache after cilostazol medication. Most normal participants complained severe headache despite oral analgesic treatment. Moreover, two of 20 smokers dropped out due to severe headache.

In conclusion, the administration of cilostazol improves the vasodilatory response to reactive hyperemia in the smokers.

**References**

1. Celermajer DS. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 1997;30:325-33.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nat Rev 1993;362:801-9.
3. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OL, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-5.
4. Jeong YH, Lee SW, Choi BR, Kim IS, Seo MK, Kwon CH, Hwang JY, Park SW. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009;53:1101-9.
5. Kelm M. Flow-mediated dilatation in human circulation: diagnostic and therapeutic aspects. Am J Physiol Heart Circ Physiol 2002;282:H1-5.
6. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thulliez C, Luscher TF. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1993;91:1314-9.
7. Wang T, Elam MB, Forbes WP, Zhong J, Nakajima K. Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication. Atherosclerosis 2003;171:337-42.
8. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-86.
9. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
10. Cooke JP, Tsao PS. Is NO an endogenous antithromogenic molecule? Arterioscler Thromb 1994;14:653-5.
11. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997;79:350-4.
12. Ghiaodini L, Donald AE, Cropley M, Mullen MJ, Oakley G, Taylor M, O’Connor G, Betteridge J, Klein N, Steptoe A, Deanfield JE. Mental stress induces transient endothelial dysfunction in humans. Circulation 2000;102:2473-8.
13. Lekakis J, Papamichail C, Vemmos C, Nanas J, Kontoyannis D, Stamatelopoulos S, Moulopoulos S. Effect of acute cigarette smoking on endothelium-dependent brachial artery dilatation in healthy individuals. Am J Cardiol 1997;79:529-31.
14. Kawano H, Motoyama T, Hinashima O, Hinz N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H. Hyperglycemia rapidly sup-
presses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34:146-54.
15. Bevan JA. Flow regulation of vascular tone. Its sensitivity to changes in sodium and calcium. Hypertension 1993;22:273-81.
16. Mombouly JV, Vanhoutere PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999;31:61-74.
17. Loll-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furfie K, Gillespie C, Go A, Greenlund K, Haase N, Hielpert S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozafarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Thom T, Waterthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation 2010;121:e66-e215.
18. Doll R, Petro R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004;328:1519.
19. Ambrose JA, Banaa RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004;43:1731-7.
20. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 2003;46:91-111.
21. Hill JM, Zalos G, Halcox JP, Schenke WH, Wacławiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:591-600.
22. Hadi HA, Cart CA, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005;1:183-98.
23. Johnson HM, Gossett LP, Piper ME, Aeschlimann SE, Korcarz CE, Baker TB, Fiore MC, Stein JH. Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2010;55:1988-95.
24. Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition restores endothelial dysfunction in heavy smokers. Circulation 2003;107:416-21.
25. Oida K, Ebata K, Kakenara H, Suzuki J, Miyamori I. Effect of cilostazol on impaired vasodilatory response of the bronchial artery to ischaemia in smokers. J Atheroscler Thromb 2003;10:93-8.
26. Yasuda K, Sakuma M, Tanabe T. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. Arzneimittelforschung 1985;35:1198-200.
27. Haart WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608-21.
28. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun JK, Park SJ. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008;51:1181-7.
29. Ikeda U, Ikeda M, Kano S, Kanbe T, Shimada K. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. Eur J Pharmacol 1996;314:197-202.
30. Nakamura T, Houchi H, Minami A, Sakamoto S, Tsuchiya K, Niwa Y, Minakuchi K, Nakaia Y. Endothelium-dependent relaxation by cilostazol, a phosphodiesterase III inhibitor, on rat thoracic aorta. Life Sci 2001;69:1709-13.